MOUNJARO® 10mg KwikPen®, 1 Stk.

Description

Name: MOUNJARO® 10mg KwikPen®, 1 Stk.
Manufacturer: Eli Lilly and Company Limited
Active Substance(s): TIRZEPATIDE
Strength: 10mg/0.6ml injection
Package Content: 1 box with 4 pre-filled KwikPens

MOUNJARO® 10mg KwikPen is a once-weekly tirzepatide injection in a pre-filled pen, supporting intensified glycaemic control and weight loss in adults with type 2 diabetes across EU and US markets. The 10mg strength is used as a maintenance or further titration dose for patients who have successfully completed lower initiation steps. For those looking to buy MOUNJARO® 10mg KwikPen online, the Maylips support team is more than happy to provide guidance.

MOUNJARO® 10mg KwikPen contains tirzepatide at 10mg per 0.6mL dose, a dual GIP and GLP-1 receptor agonist developed by Eli Lilly and Company, indicated for adults with type 2 diabetes mellitus and — in jurisdictions where locally authorized — for weight management in eligible adults [3][4]. Each multi-dose pre-filled pen delivers four once-weekly subcutaneous injections via a single needle, with the April 2026 device redesign providing improved end-of-use confirmation without altering the tirzepatide formulation or dosing schedule. Licensed practitioners looking to buy MOUNJARO® 10mg KwikPen online can reach the Maylips support team for product information and ordering guidance.

Product Specifications

• Strength: 10mg per dose (0.6mL)
• Active Ingredient: Tirzepatide
• Dosage Form: Multi-dose pre-filled pen delivering 4 doses of 10mg tirzepatide (0.6mL per dose); single needle per injection
• Device: KwikPen with four pre-filled doses
• Administration: Once weekly
• Manufacturer: Eli Lilly and Company
• Initial U.S. Approval: 2022
• Molecular Class: Dual GIP/GLP-1 receptor agonist
• Indications: Type 2 diabetes mellitus management in adults; weight management in adults where locally authorized

MOUNJARO® 10mg KwikPen is a prescription medicine containing tirzepatide, the first approved agent to activate both the GIP and GLP-1 receptors through a single synthetic peptide [3]. Each multi-dose pre-filled pen holds 40mg tirzepatide in 2.4mL total, delivering four fixed doses of 10mg per 0.6mL once weekly. The 10mg dosage is typically introduced after patients have completed lower titration steps and demonstrated satisfactory tolerability, positioning it as a maintenance or further-escalation dose within the MOUNJARO® treatment pathway [3].

In the U.S., MOUNJARO® is FDA-approved for adults with type 2 diabetes mellitus as an adjunct to diet and exercise [3]. In the EU, the European Commission granted marketing authorization for MOUNJARO® following a positive EMA opinion covering type 2 diabetes mellitus and weight management in adults [4][5]. In the U.S., tirzepatide for weight management is authorized under a separate brand name, MOUNJARO®; it covers only type 2 diabetes mellitus [3].

The April 2026 hardware update revised the delivery device without changing the medicine. Patients transitioning from earlier pen versions continue on the same prescribed dose and injection schedule.

Eli Lilly introduced a redesigned KwikPen device across all MOUNJARO® strengths in April 2026, in markets where the multi-dose pen format is available. The revision is limited to the pen hardware; the tirzepatide formulation, concentration, approved indications, and once-weekly dosing schedule are unchanged.

Two changes define the updated device:

• Extended internal plunger: A new internal component added behind the plunger increases its length, providing clearer visual confirmation that each weekly dose has been fully delivered.
• End-of-use indicator: After the fourth and final injection, the plunger advances close to the pen tip — a clear signal the device is depleted and should be discarded.

The redesign also eliminates residual liquid that some patients were extracting from older pen models as an unofficial fifth dose, sometimes called the “golden dose.” Practitioners should walk patients switching from earlier MOUNJARO® devices through these differences before the first administration with the updated pen. Clinical performance, pharmacokinetics, and the established safety profile are unaffected.

Tirzepatide is a synthetic peptide that simultaneously engages the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor via independent binding domains on a single molecule [3]. Activating both incretin pathways in tandem gives tirzepatide a broader metabolic reach than agents that target the GLP-1 receptor alone [3].

GLP-1 receptor activation drives glucose-dependent insulin secretion, suppresses glucagon output, and slows gastric emptying — reducing postprandial glucose in adults with type 2 diabetes mellitus [3]. GIP receptor activation enhances insulin responsiveness, modulates adipose lipid metabolism, and may reduce the gastrointestinal burden associated with GLP-1 monotherapy [3].

In the SURPASS-2 trial, tirzepatide produced greater reductions in HbA1c and body weight than once-weekly semaglutide in adults with type 2 diabetes [2]. Across the SURMOUNT program, tirzepatide also demonstrated significant body weight reduction in adults with obesity, supporting its use in weight management where locally authorized [1]. Because insulin secretion under tirzepatide is glucose-dependent, the standalone risk of hypoglycemia is generally low; that risk increases when tirzepatide is co-administered with insulin or sulfonylureas [3].

MOUNJARO® 10mg KwikPen is indicated as an adjunct to diet and exercise for glycemic improvement in adults with type 2 diabetes mellitus [3]. In the EU, the marketing authorization covers weight management in adults with a body mass index of 30 kg/m² or above, or 27 kg/m² or above with at least one weight-related comorbidity, as an adjunct to a reduced-calorie diet and increased physical activity [4]. In the U.S., tirzepatide for weight management is authorized under a separate brand name: MOUNJARO®; it is indicated for type 2 diabetes mellitus only [3].

FLAG: Client to verify that the EU indication wording above matches the current EMA label exactly before publication.

Clinical considerations before prescribing or continuing at the 10mg dose:

• Dose history: The 10mg strength follows lower titration steps; tolerability and response at prior doses should be confirmed before escalation or maintenance at this level [3].
• Monitoring: Track glycemic control, body weight, renal function, and signs or symptoms of pancreatitis, gallbladder disease, or diabetic retinopathy throughout treatment [3].
• Demographic data: SURPASS subgroup analyses show consistent efficacy across age, gender, race, and ethnicity groups [2].
• Exclusions: MOUNJARO® is not indicated for type 1 diabetes mellitus or diabetic ketoacidosis and should not be co-prescribed with other GLP-1 receptor agonists.

All prescribing should follow the current regional product information applicable to the practitioner’s jurisdiction. Practitioners who plan to buy weight loss medicine for eligible patients can reach out to the Maylips support team for guidance on available options.

MOUNJARO® 10mg is administered once weekly by subcutaneous injection using a single needle per dose. Approved sites — abdomen, thigh, and outer upper arm — should be rotated at each administration to minimize localized reactions [3]. The multi-dose pre-filled pen delivers a fixed 10mg dose per activation and is intended for single-patient use, with no manual preparation required between injections.

Practitioners looking to buy MOUNJARO® for eligible patients can contact the Maylips support team for guidance on available strengths, procurement, and supply guidelines.

Key administration guidance to communicate to patients:

• Pre-injection inspection: The solution should appear clear and colorless, free from visible particles or discoloration, before each use [3].
• Injection technique: Press the activation button and hold the pen against the skin for approximately 10 seconds; verify the dose window before removing the pen [3].
• Oral medication timing: Tirzepatide delays gastric emptying and may affect absorption of oral medicines with narrow therapeutic windows; timing adjustments may be warranted [3].
• Missed doses: A missed dose may be administered within four days of the scheduled date. Beyond that window, skip the dose and resume the regular weekly schedule; do not administer an additional injection to compensate [3].

Discard the KwikPen after the fourth dose. Where the April 2026 redesign applies, the plunger position near the pen tip confirms the device is depleted.

Adverse reactions to MOUNJARO® 10mg are mostly mild-to-moderate gastrointestinal symptoms—such as nausea, vomiting, diarrhea, constipation, decreased appetite, and abdominal discomfort—which usually decrease once a stable dose is maintained [3]. Localized injection-site reactions, such as redness or swelling, may also occur but typically resolve on their own [3]. Less common but serious risks include pancreatitis, gallbladder disorders, and acute kidney injury from dehydration [3]. While standalone hypoglycemia risk is low, it increases if MOUNJARO® is combined with insulin or sulfonylureas, requiring potential dose adaptations for those co-prescribed therapies [3].

Boxed Warning / Contraindication

Tirzepatide causes thyroid C-cell tumors in rodents; human risk is unknown. MOUNJARO® is strictly contraindicated in patients with a personal or family history of Medullary Thyroid Carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2) [3].

MOUNJARO® is subject to additional regulatory monitoring [4]. Healthcare professionals should report suspected adverse events via local pharmacovigilance channels, such as the UK’s MHRA Yellow Card Scheme or the EU’s EudraVigilance system, and consult full regional prescribing metrics before treatment initiation [4].

MOUNJARO® 10mg KwikPen is a prescription-only medicine. Supply is restricted to licensed healthcare professionals and authorized healthcare facilities.

• United States: MOUNJARO® received initial FDA approval in 2022 for adults with type 2 diabetes mellitus as an adjunct to diet and exercise [3]. In the U.S., tirzepatide for weight management is authorized under a separate brand name.
• European Union: The European Commission granted marketing authorization for MOUNJARO® (tirzepatide) following a positive opinion from the EMA [4][5]. The authorization covers type 2 diabetes mellitus and weight management in adults per the approved EU product information [4]. FLAG: Client to verify final EU indication wording against the current EMA label before publication.
• United Kingdom: Prescribing follows guidance issued by the Medicines and Healthcare products Regulatory Agency (MHRA). Adverse reactions should be reported through the Yellow Card Scheme where applicable.

When buying online, licensed practitioners should confirm the regulatory status, approved indications, and jurisdiction-specific supply conditions applicable to their market before placing orders. All prescribing and dispensing must align with the most current regional product information.

1. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
2. Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine. https://www.nejm.org/doi/full/10.1056/NEJMoa2107519
3. S. Food and Drug Administration. MOUNJARO (tirzepatide) injection, for subcutaneous use. DailyMed. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0
4. European Medicines Agency. Mounjaro: INN: tirzepatide. EMA Product Information. https://www.ema.europa.eu/en/documents/product-information/mounjaro-epar-product-information_en.pdf
5. European Commission. Commission Implementing Decision granting marketing authorisation for Mounjaro — tirzepatide. 2022. https://ec.europa.eu/health/documents/community-register/2022/20220915156773/dec_156773_en.pdf

All content on this website is intended for informational purposes and does not constitute medical advice.

Warning! The product is intended solely for professional use in a medical environment and under professional supervision. The product is supplied to medical professionals who specialize in aesthetic medicine (plastic surgery, facial treatments) and work under individual medical licenses as aestheticians or in dedicated clinics. Unprofessional use by individuals without a medical background may lead to severe adverse effects and health harm.